Regulation & Compliance

New data on leronlimab reveals striking long-term survival signals in heavily pretreated mTNBC patients, hinting at a new way to fight the disease.

Mayors Johnson and Frey join Robert De Niro in a live counter-event aiming to 'speak over' the SOTU, marking a new, direct form of political opposition.

Fintech innovator Capitolis is set to acquire a 15-year-old U.S. secured financing platform, a strategic move to expand its Capital Marketplace.

After a period of uncertainty, the digital asset firm has regained compliance with Nasdaq's bid price rule, a key step for its institutional ambitions.

With a 10x surge in transaction volume, Pay Protocol's success on TRON highlights a quiet revolution in business finance, powered by stablecoins.

New research reveals how clinical trial design inflates the placebo effect, offering a key to solving the 90% failure rate for anxiety and depression drugs.

Cannabis giant Green Thumb Industries expands its credit facility to $189M, signaling strong lender confidence and fueling its strategic growth ambitions.

The biotech firm landed $1M at a premium, a sign of investor faith. But with past regulatory hurdles, can this cash pave a new path for its NurOwn® therapy?

The REIT is offering a high 9.75% yield for new notes, but investors who refuse the swap could see their current protections vanish. A critical choice looms.

A legacy financial educator pivots to digital assets with a hands-on course, but can it overcome the shadow of its predecessor's FTC lawsuit?

A new partnership will supply Japan's surging cell therapy sector with critical, GMP-grade materials, aiming to accelerate the path from lab to clinic.

A landmark agreement sees Tla’amin Nation acquire a massive forest tenure, blending traditional stewardship with a new model for BC's forestry industry.

A federal court ruling against Corcept Therapeutics clears a key legal hurdle for Teva's generic Cushing's syndrome drug, rattling investors.

Travere Therapeutics reports a profitable Q4 driven by its kidney drug FILSPARI, but a revenue miss and a critical FDA decision create a complex outlook.

ACIC posts a 41% surge in annual net income, crushing guidance with savvy reinsurance moves and a laser focus on its core Florida commercial market.

As AI adoption outpaces policy, a new legal practice aims to bridge the governance gap, offering a practical playbook for businesses in a new legal frontier.

Wytec International's new AI safety platform promises to protect schools and cities, but raises critical questions about privacy and mass surveillance.

The Hume Band challenges rivals with a no-subscription model and longevity tracking, but user complaints and questions about its tech cloud its bold promises.

The French spirits group reports a sharp 8.6% drop in 2025 revenue, hit by a global slowdown, delistings of its William Peel brand, and intense pricing pressure.

Mayo Clinic implements Dock Health's platform to automate workflows, reduce clinician burden, and ensure patient care plans don't fall through the cracks.